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Electronic cigarettes (ECIGs) operate by heating a nicotine-containing solution 
resulting in an inhalable aerosol. Nicotine delivery may be affected by users’ puffing 
behavior (puff topography), and little is known about the puff topography of ECIG users. 
The purpose of this study was to examine the extent to which a mouthpiece-based 
topography measurement device influences the acute effects associated with ECIG use.  
Twenty-nine experienced ECIG users completed two sessions differing only by 
the presence of a mouthpiece-based topography recording device. In both sessions, 
participants completed one 10 puff, 30 sec inter-puff interval (IPI) ECIG-use bout and 
  
 
another 90 minute ad libitum bout. Acute ECIG effects (plasma nicotine concentration, 
heart rate [HR], and subjective effects) were largely unaffected by the presence of the 
topography recording device. Evaluating ECIG puff topography through clinical 
laboratory methodology is necessary to understand the effects of these products 
(including toxicant exposure) and to inform their regulation. 
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Examination of Electronic Cigarette User Puff Topography: The Effect of a Mouthpiece-
based Topography Measurement Device on Plasma Nicotine and Subjective Effects.  
  
The health risks of smoking cigarettes such as lung cancer, stroke, and 
cardiovascular disorders are well documented (Mathers & Loncar, 2006). However, 
cigarette smoking remains the leading preventable cause of death resulting globally in an 
estimated 6 million, and nationally approximately 480,000 deaths per year (Agaku, King, 
& Dube, 2014). In addition, roughly $133 billion is spent annually on health care related 
expenses associated with smoking (Campaign for Tobacco-Free Kids, 2014). 
Furthermore, 18% of adults in the U.S. are current smokers (Agaku et al., 2014), and 
23% of high school and 6.7% of middle school students currently use some form of 
tobacco (CDC, 2014). Reducing tobacco consumption and increasing tobacco cessation 
therefore is a public health necessity. 
There are a variety of health benefits observed following abstinence from 
combustible tobacco. Smoking-related diseases such as cardiovascular disorders and 
cancers are primarily the result of exposure to harmful constituents of tobacco smoke 
(e.g., carbon monoxide [CO], tobacco-specific nitrosamines [TSNAs], and polycyclic 
aromatic hydrocarbons [PAHs]; USDHHS, 2014). Cessation from tobacco can greatly 
reduce smokers’ exposure to these harmful constituents, resulting in immediate (e.g. 
reduction in CO levels) and long-term health benefits (e.g., reduction in risk of certain 
lung, mouth, and esophageal cancers: Fagerström, 2002; USDHHS, 2014).  
Despite the numerous health benefits associated with smoking cessation, few 
smokers are successful in quitting. Each year, 69% of cigarette smokers in the U.S. say 
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they want to quit (CDC, 2011), and 52% make a quit attempt (Agaku et al., 2014). 
However, relapse rates are very high, with approximately 6% of smokers remaining 
abstinent (CDC, 2011), despite the availability of numerous pharmacological (e.g., 
nicotine replacement therapy [NRT]) and behavioral (e.g., cognitive behavioral therapy) 
smoking cessation treatments (Fiore et al., 2008). Smoking cessation is difficult to 
achieve primarily because another constituent of tobacco (nicotine), is a drug of abuse 
with chemically addicting properties that can promote physiological dependence 
(USDHHS, 2014).   
Influence of Nicotine on Tobacco Consumption and Abstinence Symptom 
Suppression 
Initial episodes of nicotine self-administration are thought to be reinforced 
positively (similar to other stimulant drugs such as cocaine and amphetamine). Positive 
reinforcement occurs when the addition of a stimulus (e.g., nicotine) following a behavior 
(e.g., smoking) increases the likelihood of that behavior occurring again (Glautier, 2004). 
More specifically, initial episodes of nicotine consumption stimulate the nicotinic 
acetylcholine receptors (Benowitz, 2008; Henningfield & Keenan, 1993), inducing the 
release of dopamine and other neurotransmitters, thereby increasing the likelihood that 
successive episodes of nicotine consumption will occur (Benowitz, 2008). The acute, 
positive reinforcing effects of nicotine include: mild euphoria and heightened arousal 
(Watkins, Koob, & Markou, 2000). In addition to these positive reinforcing effects, 
chronic users may continue to self-administer nicotine due to a different mechanism: 
negative reinforcement. Negative reinforcement occurs when the removal of an aversive 
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stimulus following a particular behavior increases the likelihood of that behavior 
occurring again (Eissenberg, 2004). Prolonged use of tobacco products can lead to 
physiological dependence and adverse symptoms (e.g., irritability, difficulty 
concentrating, and anxiety) following abstinence (Hughes & Hatsukami, 1986; Watkins 
et al., 2000). Thus, cigarette users may continue to smoke because smoking can suppress 
these unpleasant abstinence symptoms (Eissenberg, 2004).  
Numerous studies have demonstrated that tobacco use is often maintained in 
smokers by negative reinforcement. Cigarette smokers often cite abstinence symptoms as 
a principal reason for continuing to smoke and/or preventing them from quitting smoking 
(Cummings, Jaen, & Giovino, 1985; Gilbert, Sharpe, Ramanaiah, Detwiler, & Anderson, 
2000). In addition, several studies have revealed that smokers who experience more 
severe abstinence symptoms are more likely to continue using tobacco (Piasecki et al., 
2000; Piasecki, Jorenby, Smith, Fiore, & Baker, 2003a; Piasecki, Jorenby, Smith, Fiore, 
& Baker, 2003b; Piper et al., 2011). For example, secondary analysis of a large scale 
clinical trial that evaluated the efficacy of the 21 mg nicotine patch and bupropion for 
smoking cessation revealed that across all conditions of the study, abstinence symptom 
severity was a significant predictor of smoking relapse, suggesting that the more intense 
these smokers’ abstinence symptoms were, the more likely they were to relapse to 
combustible tobacco (Piasecki et al., 2003a).   
Several human laboratory studies have shown that various abstinence symptoms 
can be suppressed in tobacco-abstinent smokers following consumption of their own 
brand of cigarettes (Breland, Evans, Buchhalter, & Eissenberg, 2002; Breland, 
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Kleykamp, & Eissenberg, 2006; Buchhalter & Eissenberg, 2000, Vansickel, Cobb, 
Weaver, & Eissenberg, 2010). For example, an acute evaluation of the effects of own 
brand cigarettes relative to two different types of electronic cigarettes (ECIGs) and a 
sham (unlit cigarette) in 12-hour-abstinent smokers revealed that own brand cigarettes 
significantly reduced subjective measures of “urge to smoke a cigarette,” “impatient,” 
“anxious,” “irritability/frustration/anger,” “craving a cigarette,” and “restlessness” 
(Vansickel et al., 2010). In addition, non-nicotine stimuli that accompany smoking can 
suppress abstinence symptoms in the absence of nicotine. Specifically, one double blind 
study revealed that over a five-day period, participants using de-nicotinized cigarettes 
reported reductions in the subjective items “urge to smoke a cigarette,” “desire for 
sweets,” and “ hunger” (Buchhalter, Acosta, Evans, Breland, & Eissenberg, 2005). 
Tobacco abstinence symptoms can also be suppressed by pharmacologically pure 
nicotine (Evans, Blank, Sams, Weaver, & Eissenberg, 2006; Kleykamp, Jennings, Sams, 
Weaver, & Eissenberg, 2008; Teneggi et al., 2002). In one clinical examination of the 
acute effects of the nicotine patch in 8-hour-abstinent smokers, abstinence symptoms 
were suppressed following patch administration in a dose-dependent manner (Kleykamp 
et al., 2008). The results of these and related studies concerning the relationship between 
pharmacologically pure nicotine and abstinence symptom suppression in smokers have 
led to the utilization of NRT as a tobacco cessation aid.  NRTs can increase short-term 
cessation rates by 50 - 70%, and can be administered via a nicotine patch, nicotine 
lozenge, nicotine gum, nicotine nasal spray, and nicotine inhaler (Stead et al., 2012). As 
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described below, NRTs are a few of the numerous products designed to reduce tobacco-
related health risks. 
Harm Reduction 
The extremely low rates of tobacco cessation and the observation that 
pharmacologically pure nicotine can alleviate tobacco abstinence symptoms have 
prompted many public health officials to endorse harm reduction strategies to decrease 
tobacco-related morbidity and mortality and promote tobacco cessation. Harm reduction 
advocates accept that a drug will continue to be used, often noting that total abstinence 
within a population is impractical, and thus work toward reducing the adverse outcomes 
for those who continue to use the drug (Stratton, Shetty, Wallace, & Bondurant, 2001). In 
the case of tobacco, harm reduction has been attempted by altering characteristics of 
cigarettes to reduce the toxicant content of smoke. For example, Advance cigarettes 
purported to reduce users’ exposure to TSNAs (Breland, Evans, Buchhalter, & 
Eissenberg, 2002).  
The concept of harm reduction has also led to the development of alternative 
tobacco products that purportedly reduce harm associated the use of conventional tobacco 
products. These alternative products are sometimes referred to as “Potential Reduced 
Exposure Products” (PREPs) and in complying with recent legislation, the Food and 
Drug Administration has introduced the term “Modified Risk Tobacco Products” 
(MRTPs) to describe products that are modified and will be marketed with the intent to 
reduce tobacco-related morbidity and mortality (Deyton, Sharfstein, & Hamburg, 2010). 
Typically, these products are designed to reduce smokers’ exposure to harmful tobacco 
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constituents (e.g. TSNAs, PAHs, CO) but continue to deliver the addicting component of 
tobacco (nicotine). The realization that the combustion of tobacco is responsible for the 
formation of several harmful constituents in tobacco smoke (e.g. CO and PAHs) has led 
to the emergence of numerous non-combustible potential MRTPs (USDHHS, 2014). 
Examples of non-combustible potential MRTPs include: tobacco pouches (e.g. Swedish 
“snus”: Cobb, Weaver, & Eissenberg, 2010), low-nitrosamine tobacco pellets (e.g. Ariva 
and Stonewall: Blank & Eissenberg, 2010; Hatsukami et al., 2011), and nicotine-
impregnated rubber disks (e.g. Verve: Zeller, 2012). Other previous products (no longer 
on the market) that purportedly reduced toxicant exposure by heating, rather than 
combusting tobacco were Philip Morris’ Accord and R.J. Reynolds’ Eclipse (Breland et 
al., 2006; Buchhalter & Eissenberg, 2000). ECIGs are one of the newest and most 
popular types of alternative tobacco products, but their ability to reduce tobacco-related 
harm remains unclear.   
Background on ECIGS 
ECIGS were first patented in China in 2003 (Lik, 2003) and introduced into the 
U.S. market in 2007 (Regan, Promoff, Dube, & Arrazola, 2013). Since their inception, 
ECIGs have increased in popularity with use rates increasing among youth and adults 
steadily (CDC, 2013; King, Alam, Promoff, Arrazola, & Dube, 2013). In addition, ECIGs 
are featured in advertising, television, and movies (Grana, Glantz, & Ling, 2011), and 
ECIG sales in the U.S. are expected to exceed $2 billion in 2014 (Herzog & Gerberi, 
2013). Despite their rapid growth in popularity, many questions remain about ECIGs, and 
limited research has been conducted.   
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ECIGs are a class of products that typically contain some common components 
including: a power source (usually a battery) and a heating element (commonly referred 
to as an atomizer). The element heats a solution that contains solvents (e.g. propylene 
glycol and/or vegetable glycerin) and sometimes, but not always, flavorings and nicotine. 
The user inhales the resulting aerosol. Despite these common features, ECIGs vary in 
their design features and appearance considerably. For example, some ECIGs are 
designed to resemble the shape, size and color of tobacco cigarettes. These ECIG models 
are sometimes referred to as “cigalikes,” and often store the liquid solution in a cartridge. 
The cartridges often contain the heating element, and are sometimes referred to as 
“cartomizers.” Users activate the heating element of these devices simply by inhaling 
through the mouth-end of the cartridge, and a light-emitting-diode (LED) glows at the 
non-mouth end when the heating element is activated. After the solution is depleted, 
some “cigalike” models require the user to replace or refill the cartridge, while others 
require the user to dispose of the entire ECIG (Breland, Spindle, Weaver, & Eissenberg, 
2014; Etter 2012).      
Other ECIG models do not resemble cigarettes, contain rechargeable batteries, 
and either store solution in reservoirs known as “tanks” or in cartridges. Users of these 
devices can buy the refill solutions separately and refill their tank or cartridge as needed 
or can buy cartridges pre-loaded with their preferred solution. The heating element in 
these models is usually activated manually by pressing a button near the mouth-end of the 
device (Breland et al., 2014; Etter 2012). In some of these models, users can alter the 
power flowing through the heater by changing the battery’s voltage in an effort to modify 
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characteristics of the subsequent aerosol (Etter, 2012; Shihadeh, Salman, Balhas, 
Karaoghlanian, Melvani, & Eissenberg, 2013).   
In addition to varying in design features and appearance, the solutions intended 
for ECIGs also vary considerably. Nicotine concentrations of these solutions generally 
range from 0 to 36 mg/ml, and the solutions come in a variety of flavors (e.g. tobacco, 
menthol, dessert, and fruit: Breland et al., 2014; Vaperzone Inc., 2014). One recent study 
determined that there were at least 466 unique ECIG brands and 7,764 solution flavors 
(in terms of unique linguistic labels) available for purchase over the internet, and that 
these figures were increasing steadily (Zhu et al., 2014). To add to the complexity, 
discrepancies between actual and advertised nicotine concentrations have been observed 
in numerous ECIG liquids (Trehy et al., 2011).  
The viability of ECIGs as an effective harm reduction strategy remains uncertain. 
Overall, features that would likely indicate that a potential MRTP would be an effective 
harm reduction strategy at the individual level would include: (1) reduce the users’ 
exposure to harmful smoke constituents, ideally by helping smokers to quit using 
combustible tobacco completely (2) suppress abstinence symptoms as effectively as 
tobacco cigarettes, thereby facilitating tobacco cessation and (3) not be susceptible to 
compensatory behavioral changes that may undermine their harm reduction potential 
(Hatsukami et al., 2007). From a public health standpoint, ECIGs could not be considered 
a viable harm reduction option  if they: (1) encourage former cigarette smokers to 
relapse, (2) act as a gateway to conventional cigarettes for nicotine-naïve individuals, (3) 
re-normalize smoking, by undermining smoke-free laws or as a result of celebrity 
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endorsements for example, (4) expose non-users to harmful levels of ambient aerosol, (5) 
promote dual use among smokers (i.e. allowing smokers to use ECIGs in locations where 
cigarettes are banned), thereby decreasing the likelihood of tobacco cessation, and/or (6) 
result in nicotine addiction in those who are non-smokers (Fairchild, Bayer, & Colgrove, 
2014; Glynn, 2014; Maziak, 2014). Many of the public health concerns associated with 
ECIGs are difficult to assess, and may remain unanswered for several years. Therefore, 
these public health concerns are beyond the scope of this study. However, careful and 
systematic empirical evaluations of toxicant exposure (including nicotine), abstinence 
suppression, and smoking behaviors associated with ECIG-use in clinical laboratory 
settings (such as the present study) can provide insight into the viability of ECIGs as a 
harm reduction strategy for individual users. As described below, similar clinical 
evaluations of other potential MRTPs has revealed their overall impact on smokers’ 
health and harm reduction utility for individual users.  
Evaluation of Potential MRTP’s: Toxicant Exposure and Abstinence Symptom 
Suppression 
Toxicant exposure associated with the use of potential MRTPs is often examined 
to assess their utility for harm reduction. For example, exposure to nicotine and nicotine’s 
metabolite cotinine can be measured in blood plasma (e.g. Cobb et al., 2010; Evans et al., 
2006; Kleykamp et al., 2008; Vansickel et al., 2010). As previously mentioned, repeated 
administrations of nicotine can result in physiological dependence, and nicotine self-
administration can suppress the aversive symptoms smokers experience during periods of 
tobacco abstinence (Fiore et al., 2008; Stead et al., 2012). Therefore, examining nicotine 
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delivery of potential MRTPs can provide insight into their viability as harm reduction 
strategies and/or cessation aids.  More precisely, potential MRTPs likely will be most 
successful at replacing combustible tobacco cigarettes completely if they deliver nicotine 
at levels that will attenuate to abstinence symptoms and maintain use via negative 
reinforcement, thereby decreasing the likelihood of relapse to combustible tobacco. 
However, these products also should not deliver nicotine at levels that will be toxic to any 
user and ideally, the nicotine dose that they deliver will not produce positive 
reinforcement in previously nicotine-naïve users. 
 Acute evaluations of nicotine delivery from NRTs have revealed that, unlike 
cigarettes, nicotine is delivered from NRTs gradually and in most instances slowly. 
Specifically, nicotine from NRTs is absorbed through the oral mucosa, nasal mucosa, or 
skin, while nicotine from cigarette smoke is absorbed by the alveoli of the lungs (Le 
Houezec, 2003; Stead et al., 2012). Absorption of tobacco smoke by the alveoli results in 
more rapid and efficient delivery of nicotine into the bloodstream relative to mucosal or 
transdermal absorption associated with NRT use (Le Houezec, 2003). This relatively 
slow delivery of nicotine, in addition to the lack of non-nicotine stimuli associated with 
smoking, may explain why NRTs are less effective at abstinence symptom suppression 
compared to cigarettes, why they can be ineffective long-term cessation aids (Fiore et al., 
2008) and also suggests that they can be improved upon from a harm reduction 
perspective.  
In addition to measuring exposure to nicotine, assessing users’ exposure to 
harmful carcinogenic constituents found in tobacco smoke (e.g. TSNAs, PAHs, CO) is 
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often of interest when examining potential MRTPs. Exposure to metabolites of TSNAs 
can be assessed using urinalysis, but only after relatively long-term exposure due to a 
relatively long-term half-life (e.g., Benowitz et al., 2005; Breland et al., 2006). Exposure 
to CO can be analyzed in the user’s expired breath (e.g. Benowitz et al., 2005; Breland et 
al., 2006). One study examined TSNA, PAH, and CO exposure associated with the use of 
two potential MRTPs (Advance and Eclipse) that were marketed as products that could 
reduce smokers’ risk of tobacco-related disease. Advance was a combustible product 
purported to reduce users’ exposure to TSNAs while Eclipse heated two tobacco plugs at 
the tip of the device using a carbon heating element and also purported to decrease users’ 
toxicant exposure relative to conventional cigarettes. Thirty-five participants completed 
four Latin-square-ordered 5-day conditions in which they smoked either own brand, 
Eclipse, Advance, or no product. Urine was collected on days 1, 3, and 5 of each 
condition and analyzed for the TSNA metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanol (NNAL), and the PAH metabolite 1-hydroxypyrene (1-HOP), and expired air CO 
was measured each day. In addition, on days 1 and 5, participants used the products 
assigned to that condition in the laboratory. Over the course of five days, Advance 
reduced participants’ exposure to NNAL and CO relative to participants’ own brand of 
cigarettes. In the Eclipse condition, participants’ expired CO was increased while their 
NNAL levels and 1-HOP levels did not differ relative to own brand (Breland et al., 
2006). These results demonstrated that Advance, but not Eclipse, reduced toxicant 
exposure relative to participants’ own brand of cigarettes.   
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Several other studies have demonstrated the feasibility of simultaneously 
examining acute nicotine exposure and abstinence symptom suppression associated with 
using potential MRTPs (Breland, Buchhalter, Evans, & Eissenberg, 2002; Cobb et al., 
2010; Evans et al., 2006; Kleykamp et al., 2008; Vansickel et al., 2010). These studies 
have provided insight into the viability of various potential MRTPs as harm reduction 
strategies. One study examined the acute effects of several non-combustible oral tobacco 
products (Ariva, Marlboro Snus, Camel Snus, and the Commit nicotine lozenge) in 28 
abstinent smokers relative to their own brand of cigarettes and denicotinized cigarettes. 
Although the oral, non-combustible products did not expose users to CO, they did not 
suppress abstinence symptoms or deliver nicotine as effectively compared to own brand 
cigarettes (Cobb et al., 2010). Another study examined the acute effects of two potential 
MRTPs (Accord and Eclipse; both claimed to reduce tobacco-related health risks by 
heating rather than burning tobacco) relative to own brand and denicotinized cigarettes. 
Twenty 12-hour abstinent smokers participated in this four condition, Latin-squared 
design study. Results indicated that relative to own brand cigarettes, Accord was less 
effective at reducing abstinence symptoms and increasing plasma nicotine concentrations. 
Conversely, Eclipse suppressed abstinence symptoms similarly to own brand cigarettes 
and delivered significantly more nicotine relative to Accord.  However, Eclipse exposed 
users to greater amounts of CO relative to own brand cigarettes (Breland et al., 2002). 
Taken together, the results of these studies demonstrate that numerous potential MRTPs, 
some still in existence (oral, non-combustibles) and others not (Accord and Eclipse), may 
not be effective harm reduction options for smokers either due to ineffective abstinence 
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symptom suppression (e.g., oral, non-combustibles) or failure to reduce exposure to 
harmful toxicants (e.g., Eclipse).  
ECIG proponents argue that ECIGs are a viable harm reduction strategy that can 
decrease tobacco-related morbidity and mortality considerably (Hajek, 2012; Nitzkin, 
2014; Phillips, 2009). However, given the novelty of ECIGs and the substantial 
variability in their design features, much research is needed concerning their acute 
effects. The limited studies that have examined the acute effects of ECIGs in clinical 
laboratory settings are described below.   
Toxicant Exposure and Tobacco Abstinence Symptom Suppression Associated with 
ECIG Use 
The few studies that have examined the acute effects associated with ECIG use in 
clinical laboratory settings have examined nicotine and CO exposure and abstinence 
symptom suppression primarily (Dawkins & Corcoran, 2014; Farsalinos et al., 2014; 
Nides, Leischow, Bhatter, & Simmons, 2014; Vansickel et al., 2010; Vansickel & 
Eissenberg, 2013; Yan & D’Ruiz, 2015).  
Some of these studies have revealed that ECIGs deliver nicotine with different 
effectiveness, depending on the device. For example, one within-subjects design study 
examined nicotine delivery in 23 experienced ECIG users using a “cigalike” ECIG (“V2” 
ECIG with a cartomizer, battery wattage not reported) in one condition and a tank-based 
device (“ECIV”, 9 watt battery) in another. In both conditions, the devices were filled 
with the same solution (“Flavourart Maxblend,” 18 mg/ml nicotine concentration) and 
participants underwent two smoking bouts [one in which participants were instructed to 
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take 10 puffs of their ECIG with each puff separated by 30 seconds (i.e., a directed 
smoking bout), and one in which participants used the device ad libitum for 1 hour]. 
Plasma nicotine concentrations were recorded immediately after the 5 minute smoking 
bout and at 15 minute intervals in the ad libitum bout. The “cigalike” model delivered 
significantly less nicotine (ng/ml) to the user than the tank-based ECIG model at each 
time point including after the 5 min bout (cigalike condition, M =4.9, SEM = 0.5; tank 
condition, M = 6.6, SEM = 0.6) at the end of the 60 min ad libitum bout: cigalike 
condition, M =15.8, SEM = 1.2; tank condition, M = 23.5, SEM = 1.9 (Farsalinos et al., 
2014).  
Nicotine delivery associated with ECIG use also appears to be related to users’ 
smoking behaviors. Specifically, experienced ECIG users may be able to extract nicotine 
from ECIGs more effectively than ECIG naïve cigarette smokers. One study examined 
nicotine delivery in eight experienced ECIG users using their own devices (all of which 
were tank or cartridge-based models) using two smoking bouts (identical to Farsalinos et 
al., 2014). After the 5-minute directed bout users average plasma nicotine concentration 
(SEM) was 10.3ng /ml (0) while their mean plasma concentration (SEM) observed after 
60 minutes of ad libitum use was 16.3 ng/ml (5.5; Vansickel & Eissenberg, 2013). While 
the plasma concentrations observed in these experienced ECIG users were smaller than 
those seen in other reports (Farsalinos et al., 2014), these values still approached those 
typically observed in tobacco cigarette smokers. Additionally, experienced ECIG users 
are also able to obtain nicotine using “cigalike” devices (Dawkins & Corcoran, 2014; 
Farsalinos et al., 2014) whereas inexperienced users using similar devices may be unable 
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to obtain nicotine (Vansickel et al., 2010). For example, experienced users instructed to 
use a “SKYCIG” “cigalike” device with a cartridge containing a nicotine concentration of 
18 mg/ml were able to increase their plasma nicotine concentrations (ng/ml) significantly 
relative to baseline after a 10-puff, 5-minute bout (M = 6.8; SEM = 1.2) and a 60-minute 
ad libitum bout (M = 13.9; SEM = 2.1; Dawkins & Corcoran, 2014). Conversely, ECIG 
naïve cigarette smokers failed to extract nicotine from two “cigalike” devices (“NPRO,” 
18 mg cartomizer and “Hydro,” 16 mg cartomizer) after two consecutive 10-puff directed 
smoking bouts (Vansickel et al., 2010).  Further complicating the matter, nicotine 
delivery varies substantially among experienced users using the same devices (Dawkins 
& Corcoran, 2014; Vansickel & Eissenberg, 2013). For example, 10 minutes after 10 
puffs from identical “cigalike” ECIGs, participants’ plasma nicotine concentrations 
ranged from 2.5 to 13.4 ng/ml (Dawkins & Corcoran, 2014).   
Importantly, several of these studies have also demonstrated that ECIGs do not 
expose users to detectable levels of CO after use (Farsalinos et al., 2014; Nides et al., 
2014; Vansickel et al., 2010). For example, ECIG-naïve cigarette smokers using a 
“cigalike” “NJOY” ECIG were not exposed to CO after undergoing two consecutive 10-
puff, 5 minute directed bouts (Nides et al., 2014). Furthermore, CO levels did not 
increase in experienced ECIG users using a “V2” “cigalike” ECIG or an “ECIV” tank-
based model after undergoing a 5-minute, 10-puff bout and 60-minute ad libitum bout 
consecutively (Farsalinos et al., 2014).  
In each of the aforementioned ECIG studies (i.e., Dawkins & Corcoran, 2014; 
Farsalinos et al., 2014; Nides et al., 2014; Vansickel et al., 2010; Vansickel & 
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Eissenberg, 2013), at least partial abstinence symptom suppression after ECIG use was 
observed, even in instances when no nicotine was delivered to the users (Vansickel et al., 
2010). These results suggest that ECIGs may suppress tobacco abstinence symptoms 
partially by delivering non-nicotine behavioral stimuli associated with smoking (e.g. 
hand-to-mouth movements, feeling at the back of the throat, and sight of smoke-like 
aerosol).  
These results partially support the idea that ECIGs may be a viable harm 
reduction strategy, in that they can suppress tobacco abstinence symptoms and do not 
expose users to CO. However, the observed inconsistencies regarding ECIG-associated 
nicotine delivery are troublesome, to the extent that nicotine delivery to the user is a key 
feature in predicting long-term use (and preventing relapse to combustible tobacco 
cigarettes). To understand the discrepancies observed in these clinical laboratory studies 
in terms of nicotine delivery better, a detailed analysis of ECIG users’ smoking behaviors 
(i.e. puff topography) is necessary, as there may be a specific set of behaviors required to 
obtain nicotine. As described below, the measurement of puff topography has been 
critical to understanding the effects of other products marketed with claims of harm 
reduction.  
Evaluation of Potential MRTPs: Puff Topography 
Puff topography is the quantitative measurement of individuals’ puff behaviors, 
including puff number, puff duration, puff volume, puff velocity (flow rate), and interpuff 
interval (IPI; Blank, 2008). The measurement of puff topography is critical when 
examining the effects of conventional cigarette and potential MRTP use because nicotine 
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intake, as well as the intake of other harmful smoke constituents, is largely determined by 
the manner in which products are used (Gust & Pickens, 1982; Herning, Jones, Benowitz, 
& Mines, 1983).  
The importance of puff topography analysis is perhaps best illustrated by the 
example of so-called “low yield” cigarettes. Despite being marketed to reduce smoking-
related health risks and exposure to harmful smoke constituents, “low-yield” cigarettes 
were not evaluated initially, contributing to the widespread misconception that these 
products are healthier, when in fact few, if any, positive health benefits are associated 
with these products.  Historically, machine-based smoking techniques that failed to 
consider variability in users’ smoking behaviors have been used to assess toxicant 
exposure. For example, the Federal Trade Commission (FTC) method for estimating 
cigarette toxicant exposure consists of machine-smoking a cigarette in a standardized 
procedure (i.e., 2 second, 35 ml puffs are performed until the cigarette reaches a length of 
23 mm) and then analyzing the toxicant content of the resulting smoke (Hoffmann, 
Djordjevic, & Hoffman, 1997; FTC, 2000). Based on the content of the smoke, cigarettes 
can be classified into one of several categories: “full flavor,” “low-yield,” etc. Puff 
topography analysis in several studies has revealed that the FTC method of measurement 
is not predictive of actual toxicant exposure (including nicotine), because it does not 
account for the high variability in human puffing behaviors and/or compensatory 
smoking behaviors observed in smokers that switch from “full flavor” to “low-yield” 
cigarettes (Baldinger, Hasenfratz, & Battig, 1995; Gust & Pickens, 1982; Herning, Jones, 
Bachman, & Mines, 1981; Zacny & Stitzer, 1988). For example, one study examined puff 
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topography in 24 abstinent cigarette smokers using three cigarettes which differed by 
nicotine yield (“low,” “medium,” and “full flavor”) but remained constant in terms of tar 
and CO yields and taste. Puff topography analysis showed that when using the “low-
yield” cigarettes, users took puffs of greater volume, thus resulting in CO delivery similar 
to cigarettes that were not “low-yield” (Herning et al., 1981). Another such study 
examined puff topography in six smokers using cigarettes that differed again only by 
FTC-predicted nicotine yield. Smokers in this study underwent a two-day period of ad 
libitum use followed by three experimental sessions. Within each session, participants 
smoked two cigarettes ad libitum with nicotine yields of 0.3 (“low-yield”) 1.3 (“medium-
yield”) or 2.5 (“full flavor”). Results revealed that as FTC-predicted nicotine yield 
decreased puff volume, puff duration, puff number, and CO exposure increased (Gust & 
Pickens, 1982). The results of these studies indicate that smokers may alter their smoking 
behaviors when switching to “low-yield” cigarettes, possibly in an attempt to titrate their 
nicotine intake. The compensatory smoking behaviors observed when users switch to 
“low-yield” cigarettes results in toxicant exposure that can approximate that of 
conventional “full flavor” cigarettes, undermining their harm reduction potential. 
Topography data obtained from smokers in laboratory settings can be used to 
estimate toxicant exposure more accurately than the FTC method. For example, one study 
examined nicotine and tar yields produced from “low-yield,” “medium-yield,” and “full 
flavor” cigarettes by programming a smoking machine to either puff according to: 
topography parameters normally used by the FTC method or topography data obtained 
from actual smokers. Results demonstrated that the FTC method underestimated toxicant 
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exposure and individual variability in topography considerably. Indeed, nicotine and tar 
yields based on topography data from actual smokers were 2-3 times higher than 
predicted by the FTC method (Djordjevic, Hoffmann, & Hoffman, 1997).  
These studies highlight the importance of puff topography analysis in 
understanding the use and toxicant exposure associated with combustible tobacco 
products. However, the methodologies used to measure topography can differ 
substantially.  
Measurement of Puff Topography 
Initial research regarding the analysis of smoking behaviors relied on macro-level 
aspects of cigarette consumption (e.g., cigarettes smoked per day). However, as revealed 
by more detailed analysis of puff topography (e.g., Gust & Pickens, 1982; Herning et al., 
1983), such macro-level measures do not account for the variability in smoking behavior 
and therefore are poor predictors of toxicant exposure (Guyatt, Kirkham, Mariner, 
Baldry, & Cumming, 1989). The two most common methodologies for measuring puff 
topography (i.e. observational and mouthpiece-based desktop devices) are described 
below.  
Puff topography can be measured via observational methods. Specifically, 
smoking bouts can be video recorded in a laboratory setting enabling trained video 
scorers to measure several topography variables (i.e., puff number, puff duration, and 
IPI). Several studies that have examined puff topography via observational methods have 
used multiple video scorers and demonstrated high inter-rater reliability, indicating the 
reliability of direct observation as a topography measurement tool (Frederiksen, Miller, & 
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Peterson, 1977; Lichtenstein & Antonuccio, 1981; Blank, Disharoon, & Eissenberg, 
2009). However, observational methods are labor intensive and time consuming. The 
authors of one study noted that the video scoring process lasted approximately 240 hours 
(Blank et al. 2009). Additionally, observational methods cannot be used to examine the 
topography measures of puff volume or puff velocity.  
Because of the shortcomings of observational topography analysis, researchers 
have developed more precise and efficient instruments for measuring puff topography. 
The most commonly used versions of these instruments require cigarettes to be placed in 
a specialized mouthpiece that can detect flow-induced pressure changes across an orifice 
in the mouthpiece as a result of an inhalation. The pressure changes are sensed by a 
pressure transducer and converted to flow rate (puff velocity) via previously calibrated 
software. The converted flow rate measurements subsequently are used by the software to 
calculate other puff topography variables (puff duration, IPI, volume, and number: Blank, 
2008). Portable mouthpiece-based topography recording devices that operate via similar 
mechanisms (i.e., calculating topography variables based on changes in flow rate) have 
also been used and validated (see: Blank, 2008). Numerous laboratory studies have 
demonstrated the reliability of mouthpiece-based devices such as the Clinical Research 
Support System for Laboratories (CReSS) for measuring topography in cigarette smokers 
(Blank et al., 2009; Buchhalter & Eissenberg, 2000). Furthermore, at least one study has 
demonstrated high reliability in measurement of topography recorded in cigarette 
smokers’ between mouthpiece-based and observational methods (Blank et al., 2009). 
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However, as described below, the ability of mouthpiece-based devices to measure ECIG 
topography accurately has not been reported previously and may pose several challenges.   
Puff Topography of ECIGs 
Measuring ECIG topography using extant mouthpiece-based systems such as 
CReSS may be challenging for several reasons. First, the mouthpieces used by 
computerized topography measurement systems may alter ECIG-associated nicotine 
delivery. The aerosol produced by ECIGs may condense inside the mouthpiece, 
inhibiting nicotine delivery and/or altering user behavior and effects.  
Second, the results of the few studies that have examined puff topography in 
ECIG users using observational methods suggest that the topography of experienced 
ECIG users may differ from that of tobacco cigarette smokers (Farsalinos, Romangna, 
Tsiapras, Kyrzopoulos, & Voudris, 2013; Hua, Yip, & Talbot, 2013) and these 
differences may challenge the capabilities of topography measurement systems used for 
combustible tobacco products. One of these studies examined puff duration in 80 
participants (35 smokers, 45 ECIG users) using a second generation ECIG (“eGo-T;” 
solution nicotine concentration: 9 mg/ml). ECIG users completed one 20 minute ad 
libitum ECIG-use bout, while cigarette smokers completed one 10 minute ad libitum 
ECIG-use bout and another bout in which they smoked two identical cigarettes provided 
by the researchers ad libitum. Cigarette smokers took significantly shorter puffs when 
using an ECIG (M = 2.4 sec) and when smoking cigarettes (M = 2.1 sec) relative to 
experienced ECIG users using an ECIG (M = 4.2 sec: Farsalinos et al., 2013). Another 
study utilized YouTube videos to quantify puff topography of individuals using 
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conventional cigarettes (N = 9) and ECIGs (N = 64). Again, ECIG users took 
significantly longer puffs (M = 4.3 sec) compared to cigarette smokers (M = 2.4 sec). 
ECIG users also exhibited large variability in puff durations (range: 1.9 – 8.3 sec: Hua et 
al., 2013).  
In addition to the longer puff durations observed in ECIG users relative to 
cigarette smokers, some pilot research using the mouthpiece-based system CReSS 
suggests that ECIG users may also exhibit lower flow rates. The mean peak flow (or 
maximum flow rate) of a small sample of ECIG users (N = 4) using their preferred 
device/liquid combination was 18.4 ml/sec, whereas peak flow rates observed in cigarette 
smokers typically fall into the 50 ml/sec range (Eissenberg, 2014).  Low flow rate puffs 
may reduce the accuracy of puff duration and volume measured by a mouthpiece-based 
system, as these systems rely on flow rate to detect the start and end of a puff.  More 
precisely, mouthpiece-based systems are only capable of sensing a flow rate above a 
certain threshold (for CReSS, 15 ml/sec; Stewart, Vinci, Adams, Cohen, & Copeland, 
2013) meaning any portion of a puff below that threshold will not be recorded (Blank, 
2008). Some portion of a puff from an ECIG user likely will not be recorded using an 
extant mouthpiece-based system such as CReSS, given the close proximity of CReSS’s 
flow-sensing threshold to the peak flow rates observed in ECIG users (Eissenberg, 2014). 
Collectively, previous ECIG topography research suggests current computerized 
topography devices that were designed to measure cigarette topography may need to be 
altered to measure ECIG topography adequately.  
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The importance of measuring topography accurately and reliably when assessing 
potential MRTPs such as ECIGs cannot be overstated, as other studies have demonstrated 
that toxicant exposure observed in a laboratory setting (e.g., CO and nicotine exposure) 
from other tobacco products is highly correlated with toxicant yields produced by 
smoking machines programmed to puff in a way that mimics those participants’ puff 
topography (Shihadeh & Eissenberg, 2011). If this same correlation holds true for ECIGs, 
topography data recorded from ECIG users in a laboratory setting can be used to predict 
ECIG user toxicant exposure precisely. Furthermore, understanding the relationship 
between ECIG puff topography and toxicant exposure can inform ECIG users, regulatory 
agencies, and researchers of specific puffing behaviors necessary to minimize harm 
associated with the novel product while maximizing its ability to substitute completely 
for more harmful products, like tobacco cigarettes. 
Statement of the Problem 
 ECIGs are rapidly growing in popularity, but little is known about them and few 
clinical evaluations have been conducted. Previous clinical laboratory studies have been 
crucial in understanding toxicant exposure (including nicotine), tobacco abstinence 
symptoms, and behavioral changes associated with the use of numerous other potential 
MRTPs. Some research has demonstrated that nicotine delivery from ECIGs varies, 
depending on the device and user behavior, and that ECIGs are capable of suppressing 
tobacco abstinence symptoms. For example, ECIG naïve cigarette smokers may be 
unable to obtain nicotine from certain ECIGs (Vansickel et al., 2010), whereas 
experienced ECIG users are capable of obtaining nicotine using their preferred devices 
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(Vansickel & Eissenberg, 2013). Furthermore, nicotine delivery varies among 
experienced ECIG users substantially. Analysis of users’ puffing behaviors (i.e., puff 
topography) may increase our understanding of the variability in ECIG-associated 
nicotine delivery, as it has been critical to understanding the use of other novel tobacco 
products (Gust & Pickens, 1982; Herning et al., 1983). Puff topography of cigarette 
smokers can be analyzed by computerized measurement systems that require a 
specialized mouthpiece. While there have been a limited number of studies that have 
attempted to measure ECIG topography using computerized measurement systems 
designed for measuring cigarette smokers’ puff topography (e.g., Behar, Hua, & Talbot, 
2015; Lee, Gawron, & Goniewicz, 2015), it is currently unknown if the mouthpiece 
required by these systems will interfere with ECIG-associated nicotine delivery, 
physiological effects, or subjective effects (including withdrawal suppression).  
The Present Study  
This study used clinical laboratory methods to compare nicotine delivery and 
subjective effects of experienced ECIG users when they use their preferred ECIG with 
and without a mouthpiece-based topography recording device. Additionally, ECIG 
topography was measured in the session in which the ECIG was attached to the 
mouthpiece-based device and compared to cigarette topography data from previous 
studies (e.g., Kleykamp et al., 2008). The topography recording device used consisted of 
modified hardware and software designed to record low flow rates puffs associated with 
ECIG use.  
Statement of Hypothesis 
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Based on the results of previous research, it was hypothesized that participants in 
the present study would take longer puff durations relative to those observed in cigarette 
smokers in other studies. Additionally, participants were hypothesized to obtain 
significantly less nicotine, and report less favorable subjective responses (including less 
abstinence symptom suppression) after ECIG use in the session in which a topography 
mouthpiece is attached to the ECIG relative to when no mouthpiece is present. 
Method 
Selection of Participants 
A total of 58 participants provided informed consent. Twenty-nine of these 
participants were ultimately not included in the final analyses. Of these non-completers, 
11 began the study but withdrew prior to completion and 16 were determined to be 
ineligible at screening and thus never began a session: seven did not meet the study 
criteria for an experienced user (e.g., used < 1 ml of ECIG liquid per day), five exhibited 
elevated blood pressure, two were discontinued due to lack of venous access, one was 
discontinued for self-reporting prescription drug use, and one was discontinued due to 
elevated HR. Additionally, two participants (who used the same ECIG solution) 
completed the study but their data were not included in the final data set due to analyses 
(as described in Breland et al., 2006) detecting no nicotine in their ECIG liquid, despite 
the liquid being advertised as containing 12 mg/ml nicotine.  
Thus, 29 ECIG-using community volunteers (22 males, 24 white) completed this 
within-subjects study and were included in the final analyses. A power analysis 
completed before the study began revealed that 30 participants should be sufficient to 
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obtain power of at least 0.80 (i.e. provide 80 % chance of detecting an effect), given the 
within-subjects design and the assumption of a medium effect size and repeated measures 
correlation greater than 0.80 for the outcome plasma nicotine (Barcikowski & Robey, 
1985). Indeed using these same assumptions, the 29 participants included in the final 
analyses were still sufficient to obtain power of at least 0.80 for the outcomes plasma 
nicotine, HR, and puff duration.  
Participants were recruited by Institutional Review Board (IRB)-approved 
advertisements and/or word-of-mouth. All experimental sessions took place at the 
Clinical Behavioral Pharmacology Laboratory (CBPL) located on Virginia 
Commonwealth University’s (VCU) medical campus. The CBPL is part of VCU’s Center 
for the Study of Tobacco Products (CSTP). In order to be eligible for the study, 
participants had to be healthy, aged 18-55 (M = 29.6; SD = 7.7), use ≤ 5 conventional 
tobacco cigarettes daily (M = 0.1; SD = 0.3), use ≥ 1 ml of ECIG solution daily (M = 2.7; 
SD = 1.4), use ECIG solution with a nicotine concentration ≥ 12 mg/ml (M = 15.0; SD = 
5.0; see Table 1), and must have used their ECIG for ≥ 3 months (M = 10.2; SD = 9.2; all 
according to self-report).  
Participants were excluded for self-reported history of chronic disease or 
psychiatric condition, regular use of a prescription medication, marijuana use >10 and 
alcohol use >25 days in the past 30, and use of other illicit drugs (e.g. cocaine, opioids, 
benzodiazepines, and methamphetamine) in the past 30 days. Women were excluded if 
they tested positive for pregnancy (by urinalysis) at screening.  
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Screening and Informed Consent Procedures 
  All interested participants took part in a two-part screening process. The first part 
consisted of a phone interview where participants were asked about their health status 
and tobacco use (see appendix A). Participants who met the requirements for the study 
were asked to come to the laboratory for an in-person screening, in which they provided 
information about their health, tobacco use, and demographic information. Additionally, 
during the in-person screening, participants provided their informed consent to participate 
in the study (see appendix B) and women provided urine for a pregnancy test.   
Participant Safety and Rights 
  The study methods and procedures involve minimal risk, and similar methods and 
procedures have been conducted numerous times at the CBPL over the course of 15 years 
without a serious adverse event. Twelve hours of nicotine abstinence may result in mild 
discomfort that is not medically dangerous. In addition, the blood drawing procedure 
involves minimal risk of bruising and/or infection at the catheter site, but these risks are 
minimized by the trained nursing staff and sterile nursing procedures. The risks and side 
effects of using ECIGs/nicotine are routine for the target population. 
  The trained CBPL staff ensured protection of participants’ safety and rights 
throughout the study. HR and blood pressure (BP) were monitored continuously and 
sessions were ended prematurely if a participant’s systolic BP dropped below 90 or above 
140 or if their HR dropped below 50 or above 120. Data were treated with professional 
standards regarding confidentiality and were identified by an alphanumeric code only and 
stored in locked rooms only available to CBPL staff.  
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Materials 
For each session, participants used their preferred ECIG device and solution. 
Participants provided their preferred ECIG and laboratory staff purchased the ECIG 
solution from each participant’s usual source (e.g. either internet or local ECIG shop). 
Table 1 lists the devices, liquid nicotine concentrations, and flavors (based on product 
labeling) that were used. The solvents used in ECIG liquids and battery voltage may 
influence nicotine yield (Kosmider, Sobczak, Knysak, & Goniewicz, 2014), so, when 
available, Table 1 also includes the advertised ratio of propylene glycol (PG) to vegetable 
glycerin (VG) and battery voltage. Because the sizes of tank and cartridge systems 
abound and therefore may not have been compatible with the mouthpiece-based 
topography system that was used, all participants were required to use a 510 cartridge 
with 1.5 ohms resistance and dual heating-coils. All cartridges were produced by 
SmokTech (Shenzhen, China) and purchased locally in Richmond, Virginia.  
Procedures 
After completion of the screening procedures (including informed consent), 
participants attended VCU’s CBPL on two days (separated by a minimum of 48 hours) to 
complete two approximately 3-hour sessions: one in which a mouthpiece-based 
topography recording device was attached to their ECIG and one in which it was not. 
Session order was counter-balanced across participants. Prior to each session, participants 
were asked to abstain from nicotine/tobacco for ≥ 12 hours. At the beginning of each 
session, participants’ expired air CO concentration was measured to verify abstinence 
from combustible tobacco (≤ 10 ppm, as in Breland et al., 2002). Because ECIGs are 
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non-combustible and therefore do not produce CO under normal conditions; retrospective 
examination of baseline plasma nicotine concentration was used to ensure abstinence. 
Ultimately, five of the 29 participants included in the final analyses were suspected to 
have not abstained from nicotine, but were included in the analyses because none of the 
results changed upon excluding them from the dataset and the higher N resulted in greater 
statistical power. Mean (SD) baseline plasma concentrations for the five participants 
suspected to have not abstained was 11.3 ng/ml (2.8) while the mean value for the 24 
who remained abstinent was 2.4 ng/ml (0.9). An independent samples t-test revealed that 
these two baseline plasma nicotine means were significantly different: t (27) = -14.6, p < 
.01. After expired air CO was measured, physiological monitoring of HR and BP 
commenced. Then, an intravenous catheter was inserted into a forearm vein, and 7 ml 
blood was sampled. Participants then completed computerized questionnaires to assess 
their nicotine withdrawal and other effects (see below). Thirty minutes after session 
onset, participants were instructed to take 10 puffs from their ECIG, with each puff 
separated by 30 seconds; an observer instructed participants when to puff and verified 
compliance. Other than the puff number and IPI, puffs were ad libitum in this initial bout. 
Immediately following the tenth puff, an additional 7 ml blood was sampled, and 
participants completed the same questionnaires again. After 10 and 20 additional 
minutes, two more 7 ml blood samples were collected. Following this fourth blood 
sample, participants completed a 1 hour and 30 minute ad libitum ECIG-use session in 
which they were instructed to take as many puffs as they liked, whenever they liked. 
During the ad libitum bout, three additional 7 ml blood samples were taken, one every 30 
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minutes. Immediately after the ad libitum bout, participants completed the same 
subjective questionnaires for a third time. Fifteen minutes after the ad libitum bout was 
completed, the eighth and final blood sample occurred, the catheter was removed, and 
participants were compensated (US $100 after first session, US $150 after second).    
Outcome Measures 
Physiological measures. All blood samples were centrifuged, stored at -70°C, 
and sent to VCU’s Bioanalytical Analysis Core Laboratories for analysis of nicotine 
concentration (limit of quantitation (LOQ) = 2 ng/ml; see Breland et al., 2006). HR was 
monitored every 20 seconds using Criticare Systems model 507, fitted with pulse 
oximeter. Participants’ expired air CO was measured via a BreathCO monitor 
(Vitalograph, Lenexa, KS).  
Subjective questionnaires. Four questionnaires were administered using a 
computerized visual analog scale (VAS), consisting of a word or phrase centered on a 
horizontal line with “not at all” on the left and “extremely” on the right. Responses were 
recorded by participants by moving a mouse cursor and clicking at any point on the 
horizontal line, with scores being expressed as a percentage of total line length. Where 
necessary, questionnaires were modified such that when the words “cigarette” or 
“smoking” appeared in the original, they were replaced by “e-cigarette” or “vaping” (a 
colloquial term for ECIG use; Hajek, Etter, Benowitz, Eissenberg, & McRobbie, 2014) 
for this study. These questionnaires were administered on three occasions during the 
study sessions: prior to ECIG use, after the directed bout, and after the ad libitum ECIG-
use bout. 
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Table 1. 
 
ECIG Device and Solution Characteristics (Based on Product Labeling and 
Manufacturer Information).  
 
Participant ECIG model Nicotine 
Concentration 
(mg/ml) 
Solvent 
ratio: 
PG/VG  
Battery 
Voltage 
Liquid Flavor 
1 i-Taste 24 50/50 N/A Peach 
2 Smoke Tech 24 80/ 20 N/A DK Blend 
3 V2 Cigs 24 N/A 4.2 Menthol 
4 Tsunami 24 30/70 N/A Persian Winter 
5 iTaste 24 50/50 N/A Van. Dr. Pepp. 
6 Vamo V2 24 0/100 N/A Gorilla Juice 
7 e-Go  24 30/70 3.3 Gold Rush 
8 e-Go T 12 30/70 3.3 Aztec 
9 e-Go 12 30/70 3.3 Cinnan-toast 
10 iTaste 18 60/40 N/A Carolina Crush 
11 Stingray 24 50/50 3.7 Pink Tornado 
12 Stingray 18 50/50 3.7 Mnky Business 
13 iTaste MVP 24 60/40 N/A Carolina Cured 
14 eGo 12 30/70 3.7 White Mousee 
15 iTaste MVP 12 30/70 N/A Persian Winter 
16 e-Go T 12 30/70 3.7 Persian Winter 
17 e-Go T 28 40/60 3.7 Spearmint 
18 e-Go T 30 70/30 3.7 Blueberry 
19 Voodoo 18 70/30 N/A Vanilla 
20 Vamo V5 16 40/60 N/A Pomegranate 
21 eGo 28 40/60 3.3 Wintergreen 
22 i-Taste 18 40/60 9.0 Colonel Custard 
23 i-Taste 12 50/50 2 Vanilla 
24 i-Taste 12 40/60 3.3 King’s barrel 
25 eGo 18 30/70 3.3 Cowboy Cut 
26 Aspire 12 30/70 4.2 Unicorn Milk 
27 iStick e-leaf 12 30/70 3.2 Cont. Breakfast 
28 iStick e-leaf 24 30/70 3.7 Smerf Vendetta 
29 Vamo V2 18 65/35 4.0 Jungle Juice 
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Hughes-Hatsukami Withdrawal Scale. Nicotine withdrawal severity and 
abstinence symptom suppression were assessed using the Hughes-Hasukami withdrawal 
scale which consists of 11 items: “Anxious,” “Craving and e-cigarette/nicotine,” 
“Depression,” “ Difficultly concentrating,” “Drowsy,” “Hunger,” “Impatient,” “Irritable,” 
“Restlessness,” “Desire for sweets,” and “Urge to use an ECIG” (Hughes & Hatsukami, 
1986, see appendix C). 
Direct Effects of Nicotine. The direct effects of nicotine scale, which assessed 
the direct effects of ECIG-associated nicotine delivery and nicotine–related side effects, 
consists of 10 items: “Confused,” “Dizzy,” “Headache,” “Heart Pound,” “Lightheaded,” 
“Nauseous,” “Nervous,” “Salivation,” “Sweaty,” and “Weak” (Evans et al., 2006). 
Direct Effects of ECIG Use. This scale, adapted from the “Direct Effects of 
Tobacco” scale (Breland et al., 2006), was developed with items reported in studies 
assessing the subjective effects of smoking (e.g. Foulds et al., 1992; Pickworth, Bunker, 
& Henningfield, 1994). This scale consists of 10 items: “Did the e-cigarette  make you 
feel more awake?,” “ Did the e-cigarette calm you down?,” “Did the e-cigarette help with 
concentration?,” “Did the e-cigarette make you dizzy?,” “Was the e-cigarette pleasant?,” 
“Did the e-cigarette reduce hunger?,” “Would you like another e-cigarette right now?,” 
“Was the e-cigarette satisfying?,” “Did the e-cigarette make you sick?,” and “Did the e-
cigarette taste good?” 
Acceptability Questionnaire. Finally, in the topography mouthpiece condition, 
this questionnaire used six VAS items to assess the degree to which the topography 
equipment: “Altered e-cigarette use behavior,” “Made vaping less likely,” “Reduced 
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enjoyment,” “Affected e-cigarette taste,” “Increased awareness,” and “Increased vaping 
difficulty” (as in Blank et al., 2009). 
  Puff topography. Puff topography measurements including puff volume, 
duration, number, IPI, and flow rate (a.k.a. puff velocity) were made using an ECIG 
topography instrument developed and manufactured at the American University of Beirut 
(AUB). This instrument operated similarly to commercially available cigarette 
topography instruments (e.g., CReSS, see introduction and Blank, 2009). Importantly, the 
mouthpiece’s orifice dimensions and pressure-sensing transducer provided sensitivity 
sufficient to ensure valid measurements at puff velocities as low as 3 ml/sec because 
topography devices used to study tobacco cigarette smoking behavior may not be 
sensitive enough to measure ECIG topography accurately (Eissenberg, 2014). For 
example, CReSS, the most commonly used mouthpiece-based device for measuring 
cigarette smokers’ puff topography, has a flow-detecting threshold of 15 ml/sec (Stewart 
et al., 2013). 
  Several mouthpieces were manufactured for the device that fit the cartomizer type 
used in the current study. Each mouthpiece was calibrated separately prior to each session 
using a custom built automatic digital flow calibrator. 
Data Analysis Plan 
  For plasma nicotine data, any instances where the measurement was lower than 
the assay’s LOQ was replaced with the LOQ (2 ng/ml) as in previous work (e.g., 
Vansickel et al., 2010), as this method was a more conservative approach than identifying 
each value below the LOQ as zero. Prior to analysis, HR data were averaged to produce a 
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single value for the five minutes prior to each ECIG-use bout and prior to each blood 
draw (10 values in total). One participants’ HR data was incomplete due to an equipment 
malfunction and were thus excluded from the HR analysis. At the end of each ECIG use 
session with the mouthpiece, the topography instrument software integrated puff velocity 
data to produce the topography measures puff number, puff duration, puff volume, IPI, 
and mean puff velocity (see Shihadeh, Azar, Antonios, & Haddad, 2004 for details). Prior 
to analysis, the software performed a data cleaning procedure to correct for transducer 
noise. Data cleaning consisted of combining into a single puff any two puffs that were 
separated by less than 100 ms and deleting any puffs with a duration of less than 300 ms. 
Remaining data for each measure were averaged for each participant. 
Repeated measures analysis of variance (ANOVAs) were used to examine 
subjective questionnaires, plasma nicotine, and HR data. For subjective measures that 
were administered in both conditions (i.e., Hughes-Hatsukami, direct effects of ECIG 
use, and direct effects of nicotine) two within-subject factors were included: session (with 
and without mouthpiece) and time (baseline, post-directed bout, and post- ad libitum 
bout). Data from each questionnaire item was analyzed individually. A two (session) by 
eight (time) repeated measures ANOVA was used to examine plasma nicotine, as there 
were five additional time points for this measure. A two (session) by nine (time) repeated 
measures ANOVA was used to examine HR data, as there were nine time points for this 
measure. Violations of sphericity were adjusted using Huynh-Feldt corrections, and 
Tukey’s Honestly Significant Difference (HSD) was used to analyze any significant main 
effects and interactions.   
  
35 
 
The six items assessing the influence of topography equipment, administered in 
the mouthpiece condition only, were analyzed using a paired t-test with two levels of 
time as the within-subject factor. Again, each questionnaire item was examined 
individually. Pre-ECIG use scores were not relevant for this questionnaire, as participants 
could not judge the influence of the topography equipment prior to using it.   
Independent samples t-tests were conducted to compare puff topography data 
from the mouthpiece condition in the present study to puff topography data from 123 
tobacco cigarette smokers, as described in Kleykamp et al., (2008). Paired samples t-tests 
were also conducted to compare the puff topography from the directed and ad libitum 
bouts in the mouthpiece condition. Lastly, Pearson correlation coefficients (r) were used 
to explore relationships among peak plasma concentrations in the directed and ad libitum 
bouts and participants’ liquid nicotine concentration, PG:VG ratio, and puff count (in the 
ad libitum bout only). All statistical analyses were performed using IBM SPSS (Version 
22.0). 
Results 
Statistical analyses (main effects and interactions) for all measures are displayed 
in Table 2. The main effect of time and the interaction between time and condition were 
of greatest interest, as the main effect shows the influence of ECIG use and the 
interaction shows the extent to which the effects of ECIG use over time were affected by 
the presence of a topography mouthpiece. Importantly, of all 33 measures described in 
Table 2, only two showed a significant time by condition interaction, suggesting minimal 
influence of the mouthpiece condition overall. 
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Physiological Measures 
 As Table 2 indicates, a significant main effect of time (and no significant 
interaction with condition) was observed for plasma nicotine [F (7, 196) = 36.5, p < 
.001]. Figure 1 shows the mean data for each condition and time point. Collapsed across 
condition, mean plasma nicotine concentration immediately after the directed ECIG-use 
bout (20.6 ng/ml, SEM = 2.8) was significantly greater relative to baseline (4.0 ng/ml, 
SEM = 0.7) and 10 minutes-post directed bout (11.7 ng/ml, SEM = 1.4). Collapsed across 
condition, mean plasma nicotine concentration at 30 (25.7 ng/ml, SEM = 3.5), 60 (31.2 
ng/ml, SEM = 3.7), and 90 (35.0 ng/ml, SEM = 4.3) minutes of the ad libitum bout were 
also significantly greater relative to baseline (4.0 ng/ml, SEM = 0.7) and 5 minutes-pre 
ad libitum bout (9.6 ng/ml, SEM = 1.3). Indeed, with the exception of time point 4 (5 min 
pre- ad libitum bout), all time points were significantly different relative to baseline, 
(Tukey’s HSD, p < .05).  
 For HR, Table 2 shows that there was also a significant main effect of time [F (8, 
216) = 19.8, p < .001] and no significant interaction with condition. Collapsed across 
condition, mean HR at baseline was significantly lower (66.3 bpm, SEM = 1.3) relative 
to the post-directed bout value (73.3 bpm, SEM = 1.3), and the values at 30 (73.9 bpm, 
SEM = 1.5), 60 (73.6 bpm, SEM = 1.6), and 90 (74.4 bpm, SEM = 1.7), minutes after the 
onset of the ad libitum bout (Tukey’s HSD, p < .05). With the exception of time points 4 
(5 min-pre-ad libitum) and 5 (start of ad libitum bout), all time points were significantly 
greater than baseline (Figure 2; Tukey’s HSD, p < .05).  
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Subjective Measures 
Hughes-Hatsukami Withdrawal Scale. As Table 2 indicates, significant main 
effects of time (and no significant interaction with condition) were observed for the items 
“Anxious,” “Craving,” “Depression,” “Hunger,” “Irritable,” “Restless,” and “Urge to 
Vape” [Fs > 3.3, ps < .05]. Figure 3 shows the results for “Craving,” and “Irritable” (two 
of the items with the largest F values).  
A significant condition by time interaction was observed for the item “Impatient” 
[F (2, 56) = 4.0, p < .05]. Mean values for the three time points in the no mouthpiece 
condition were: baseline: (7.3, SEM = 3.0), post-directed (5.5, SEM = 2.4), post- ad 
libitum (4.8, SEM = 2.3) while mean VAS scores in the mouthpiece condition were: 
baseline: (10.6, SEM = 3.0), post-directed (3.0, SEM = 1.6), post- ad libitum (3.9, SEM = 
2.0). Post-hoc testing (Tukey’s HSD) revealed no differences between conditions at any 
time point.  
Direct effects of nicotine. Significant main effects of time were observed for the 
items “Dizzy,” and “Lightheaded” [Fs > 6.3, ps < .01]. Post-hoc tests (Tukey’s HSD) 
revealed that collapsed across condition, the mean post-directed bout VAS score (12.2, 
SEM = 2.9) was significantly greater relative to baseline (2.7, SEM = 1.2). A significant 
main effect of condition was observed for the item “Confused” [F (1, 28) = 4.4, p < .05]. 
Collapsed across time, higher mean ratings were observed in the no mouthpiece condition 
(1.7, SEM = 0.7) relative to the mouthpiece condition (0.6, SEM = 0.2) for this item.  
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Table 2.       
Statistical Analyses Results for Plasma Nicotine and Subjective Measures 
(Directed Bout + Ad libitum bouts).  
Outcome 
measures 
 
Condition (C) 
F value 
p value Time (T)          
F value 
p value C × T  
F value 
p value  
Plasma 
nicotineª 
0.5 ns 36.5 <.001* 0.7 ns 
Heart Rateᵇ 0.1 ns 19.8 <.001* 0.7 ns 
Subjective measures  
 
Hughes-Hatsukami ᶜ 
Anxious 1.2 ns 9.0 <.001* 1.1 ns  
Craving 2.24 ns 51.7 <.001* 1.0 ns 
Depression 0.4 ns 5.4 <.05* 1.0 ns  
Difficulty 
Concentrating 
1.1 ns 3.1 ns 1.8 ns  
Drowsy 0.3 ns 0.7 ns 1.4 ns  
Hunger 0.2 ns 9.9 <.001* 0.4 ns  
Impatient 0.0 ns 5.0 <.05* 4.0 <.05*  
Irritable 1.1 ns 13.4 <.001* 0.7 ns 
Restless 2.3 ns 3.3 <.05* 1.0 ns  
Sweets 0.3 ns 0.5 ns 0.0 ns  
Urge to Vape 1.4 ns 47.6 <.001* 0.2 ns  
 
Direct Effects of Nicotine ᶜ 
Confused 4.4 <.05* 1.4 ns 0.5 ns  
Dizzy 0.1 ns 6.3 <.01* 0.2 ns  
Headache 0.6 ns 0.1 ns 0.7 ns  
Heart Pound 0.5 ns 2.3 ns 1.6 ns  
Lightheaded 0.2 ns 6.8 <.01* 1.2 ns  
Nauseous 0.3 ns 0.4 ns 0.7 ns  
Nervous 0.1 ns 1.4 ns 1.3 ns  
Salivation 0.5 ns 2.0 ns 1.0 ns  
Sweaty  0.7 ns 3.0 ns 0.7 ns  
Weak 0.0 ns 0.4 ns 0.8 ns 
 
Direct Effects of Vaping ᶜ 
Awake 1.0 ns 10.6 <.001* 1.4 ns 
Calm 1.6 ns 25.2 <.001* 0.4 ns  
Concentrate 0.0 ns 8.1 <.001* 0.0 ns  
Dizzy 0.0 ns 6.0 <.01* 0.2 ns  
Pleasant 0.8 ns 139.8 <.001* 2.8 ns 
Reduce hunger 0.3 ns 8.2 <.01* 0.3 ns  
Right Now 0.4 ns 22.7 <.001* 0.1 ns  
Satisfying 0.2 ns 127.6 <.001* 2.4 ns  
Sick 0.0 ns 0.3 ns 1.3 ns  
Taste Good 3.6 ns 130.4 <.001* 3.9 <.05*  
Note: ns = non-significant.  
ªdf C = (1, 28); df T = (7, 196); df C x T (7, 196).  
ᵇdf C = (1,27); df T = (8, 216); df C x T (8, 216).  
ᶜ df C = (1,28); df T = (2, 56); df C x T (2, 56). 
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Figure 1. Mean data (± SEM) for plasma nicotine across conditions (N = 29). ECIG-
experienced participants completed a 10-puff ECIG use bout (30 sec IPI) and a 90 min ad 
libitum bout in two conditions: with (circles) and without (triangles) a topography 
mouthpiece attached to their preferred ECIG battery. Black bars beneath the X axis 
indicate when ECIG use could occur. Filled symbols indicate a significant difference 
from baseline (-30; the first time point). All p’s < .05; Tukey’s HSD. 
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Figure 2. Mean data (± SEM) for HR across conditions (N = 28). A malfunction of the 
equipment resulted in incomplete data collection for one participant out of the 29 
completers who were used for all other analyses. ECIG-experienced participants 
completed a 10-puff ECIG use bout (30 sec IPI) and a 90 min ad libitum bout in two 
conditions: with (circles) and without (triangles) a topography mouthpiece attached to 
their preferred ECIG battery. Black bars beneath the X axis indicate when ECIG use 
could occur. Filled symbols indicate a significant difference from baseline (-0; the first 
time point). All p’s < .05; Tukey’s HSD.  
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Direct effects of ECIG use. As Table 2 indicates, significant main effects of time 
were observed for the items “Awake,” “Calm,” “Concentrate,” “Dizzy,” “Pleasant,” 
“Reduce Hunger,” “Would like another ECIG Right Now,” “Satisfying,” and “Taste 
Good.” The items with two of the largest F values “Taste Good” and “Satisfying”) are 
depicted in Figure 4. A significant condition by time interaction was also observed for the 
item “Taste Good” [F (2, 56) = 3.9, p < .05; see Figure 4]. The interaction between 
condition and time is explained by a significantly greater post-directed bout mean VAS 
score in the no mouthpiece condition (83.2, SEM = 3.5) relative to the condition with the 
topography mouthpiece present (72.7, SEM = 5.0; Tukey’s HSD, p < .05, see Figure 4). 
  A significant condition by time interaction was also observed for the item “Taste 
Good” [F (2, 56) = 3.9, p < .05; see Figure 4]. The interaction between condition and 
time is explained by a significantly greater post-directed bout mean VAS score in the no 
mouthpiece condition (83.2, SEM = 3.5) relative to the condition with the topography 
mouthpiece present (72.7, SEM = 5.0; Tukey’s HSD, p < .05, see Figure 4). 
Acceptability questionnaire. Within the mouthpiece condition, none of the six 
topography equipment items administered differed between the post-directed and post- ad 
libitum bouts: “Altered e-cigarette use behavior,”[t (28) = 1.4, p = ns], “Made vaping less 
likely,” [t (28) = 0.7, p = ns], “Reduced enjoyment,” [t (28) = 0.18, p = ns], “Affected e-
cigarette taste,” [t (28) = 1.4, p = ns], “Increased awareness,” [t (28) = -0.7, p = ns], and 
“Increased vaping difficulty” [t (28) = 0.6, p = ns].  
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Puff Topography  
 Paired samples t-tests were conducted to compare all puff topography measures 
between the directed and ad libitum bouts within the mouthpiece condition. A significant 
difference was observed for puff duration [t (28) = 3.55, p < .01], indicating that 
participants took longer puffs on average during the ad libitum bout (5.3, SEM = 0.4) 
relative to the directed bout (4.5, SEM = 0.3; Table 3). In addition, a significant 
difference was found for puff volume [t (28) = 2.46, p < .05], demonstrating that 
participants also exhibited larger mean puff values in the ad libitum (148.5, SEM = 22.2) 
compared to the directed bout (124.6, SEM = 16.6). No differences were observed 
between bouts for flow rate. Additionally, a paired samples t-test revealed no difference 
between the two conditions (i.e., no mouthpiece and mouthpiece) for puff number 
observed in the ad libitum bouts [t (28) = 0.65, p = ns; see Table 3]. As shown in Table 4, 
independent-samples t-tests were conducted to compare puff duration, volume, and flow 
rate values from the directed bout in the present study to the same variables recorded in a 
previous study in which tobacco cigarette smokers smoked their preferred brand ad 
libitum (Kleykamp et al., 2008). Results revealed significant differences for each of the 
three variables: puff duration: [t (150) = 20.29, p < .001]; puff volume: [t (150) = 8.4, p < 
.001]; and flow rate: [t (150) = -4.08, p < .001]. 
In order to examine the relationship between nicotine delivery during the ad 
libitum bout, puff topography, and various ECIG solution characteristics, exploratory 
Pearson correlations were conducted. Specifically, peak plasma concentrations during the 
ad libitum bout in the two conditions were correlated with the number of puffs taken 
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during the ad libitum bout in the corresponding condition. Correlations were also 
performed between peak plasma concentrations for each condition and PG:VG ratio and 
liquid nicotine concentration. In addition, puff volume and duration were correlated with 
peak plasma concentrations in the mouthpiece condition. No significant correlations were 
found between peak plasma concentrations in either condition and puff number, PG:VG 
ratio, or liquid nicotine concentration nor were any significant correlations found between 
puff volume or duration and peak plasma concentrations in the mouthpiece condition.   
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Figure 3. Mean ratings (+/- SEM) for two visual analog scale items from 29 experienced 
ECIG users using their preferred device and strength/flavor in two sessions that differed 
by whether a mouthpiece-based topography system was attached to the ECIG. The no 
mouthpiece condition is represented by triangles while the mouthpiece condition is 
represented by circles. Black bars beneath the X axis indicate when ECIG use could 
occur. “Craving an e-cigarette” (left) and “Irritable” (right) were from the Hughes-
Hatsukami withdrawal scale. Filled symbols indicate a significant difference from 
baseline (i.e., -30). All ps < .05; Tukey’s HSD. 
 
 
  
   
 
 
Figure 4. Mean ratings (+/- SEM) for two visual analog scale items from 29 experienced 
ECIG users using their preferred device and strength/flavor in two sessions that differed 
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by whether a mouthpiece-based topography system was attached to the ECIG. The no 
mouthpiece condition is represented by triangles while the mouthpiece condition is 
represented by circles. Black bars beneath the X axis indicate when ECIG use could 
occur. “Did the ECIG Taste Good” (left) and “Was the ECIG Satisfying” (right) were 
from the Direct Effects of ECIG-use scale. Filled symbols indicate a significant 
difference from before ECIG use (i.e., -30). An asterisk (*) denotes a significant 
difference between conditions at that time point. All ps < .05; Tukey’s HSD. 
 
 
 
 
 
 
Table 3. 
Mean (SD) puff parameters for Directed and Ad libitum ECIG-use Bouts. 
 
Condition Duration 
(s) 
Volume 
(ml) 
Flow 
Rate 
(ml/s) 
IPI (seconds) Puff number 
Mouthpiece 
    
     
   Directed 4.51* 
(1.55) 
124.56* 
(89.13) 
27.78 
(19.48) 
25.19 (1.55) 9.97 (0.12) 
   Ad lib 5.29 
(2.08) 
148.52 
(119.6) 
27.47 
(22.63) 
102.77 (63.07) 62.55 (32.34) 
Range: 10-
161 
No Mouthpiece 
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   Directed N/A N/A N/A N/A 10 
   Ad lib N/A N/A N/A N/A 62.10 (39.99) 
Range: 18-
185 
      
 
Note, for the directed bouts, IPI and puff number are kept at 10 puffs and 30 seconds 
apart. In the no mouthpiece condition, puff number was counted manually by trained 
staff. Asterisks (*) indicate a significance difference for puff duration and volume 
between the directed and ad libitum bouts in the topography condition and N/A indicates 
values that were not measured for that particular topography variable and condition. No 
differences were observed between conditions for puff number.  
 
 
 
Table 4. 
Mean (SD) puff parameters for ECIGs and Tobacco Cigarettes. 
 
 Duration (s) Volume (ml) Flow Rate (ml/s) 
ECIGs (directed 
bout, mouthpiece 
condition only) 
4.51 (1.55)* 124.56 (89.13)* 27.78 (19.48)* 
 
Tobacco Cigarettes 1.36 (0.38) 51.29 (19.22) 37.97 (9.66) 
 
 
 (Kleykamp et al., 2007, N = 123; see also Kleykamp et al., 2008). Data from cigarette 
smokers were taken from the first cigarette of a session in which no other sources of 
nicotine were available. Independent-samples T-tests (equal variances not assumed) were 
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used to compare means for puff parameters between the present study and Kleykamp, 
(2007). Asterisks (*) indicate a significance difference between ECIGs and tobacco 
cigarettes on that measure (p < .01).   
 
 
 
 
 
 
 
 
 
 
 
Discussion 
  Puff topography is a useful measure for understanding the extent to which tobacco 
products, such as combustible cigarettes, expose users to nicotine and other harmful 
smoke constituents. ECIGs are one of the newest alternative tobacco products to emerge 
in the U.S. and global market, but little is known about the acute effects of ECIGs or the 
puff topography of ECIG users. Further understanding of the puff topography associated 
with ECIG use will likely result in a better understanding of the toxicant exposure 
(including nicotine) of these products and may also inform ECIG regulatory decisions. 
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This study demonstrated the extent to which the most common method for measuring 
tobacco cigarette puff topography (mouthpiece-based computerized devices) was suitable 
for measuring ECIG puff topography while also providing valuable information 
concerning the acute effects of ECIGs.  
Measurement of ECIG User Puff Topography 
  The measurement of puff topography has been critical to understanding the 
toxicant yield as well as user toxicant exposure associated with tobacco cigarettes. For 
example, puff topography measurement was paramount to understanding that the FTC 
method for assessing cigarette toxicant exposure (consisting of using a standardized 
puffing regimen to produce smoke for subsequent toxicant analyses) largely was not 
useful because it did not use topography parameters that were similar to actual human 
behavior and it also did not account for the great deal of individual variability in smoking 
behaviors and thus often underestimated actual toxicant exposure (Djordjevic et al., 
1997). Furthermore, puff topography analyses have been critical to understanding that 
smokers often compensate by taking longer and/or larger puffs from “low yield” 
cigarettes, thus resulting in toxicant exposure (e.g., CO) comparable to that observed 
when using “full flavor” cigarettes (Gust & Pickens, 1982; Herning et al., 1981). Puff 
topography measurement has also proven to be critical to understanding the toxicant yield 
associated with ECIGs. For example, one study has demonstrated that puff duration, but 
not puff velocity, is an important predictor of ECIG nicotine yield (i.e., greater puff 
durations result in greater nicotine yields, Talih et al., 2015). However, before a 
comprehensive understanding of ECIG puff topography can be achieved, the suitability 
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of using mouthpiece-based topography measurement devices for measuring ECIG 
topography must be determined, as these devices have been critical for providing 
accurate and reliable assessments of cigarette smoker’s puff topography (Blank et al., 
2009; Buchhalter & Eissenberg, 2000).   
Suitability of Mouthpiece-Based Device  
  The present study was the first to examine whether a mouthpiece-based 
topography measurement device is applicable for the measurement of ECIG puff 
topography. ECIG-experienced participants completed two sessions that differed only by 
the presence of a mouthpiece-based topography device. Puff topography was recorded in 
the session that included the topography mouthpiece using specialized hardware and 
software developed specifically for measuring ECIG puff topography. In addition, puff 
topography variables (i.e., puff duration, volume, and flow rate) recorded in the directed 
bout of the mouthpiece condition in the present study were compared to cigarette 
smokers puff topography from a previous study (i.e., Kleykamp et al., 2008) and to puff 
topography recorded in the ad libitum bout of the mouthpiece condition. Participants’ 
puff count during ad libitum use was also recorded and compared across conditions (puff 
count was measured observationally in the no mouthpiece condition). Lastly, the extent to 
which the presence of the device influenced the acute effects of ECIG use including 
nicotine delivery, subjective effects, and physiological effects (i.e., HR) was assessed. 
  Several puff topography variables were recorded in the condition in which the 
topography mouthpiece was attached to the participants’ ECIG. Importantly, the mean 
puff duration in the directed bout of this study (4.5 s) is largely consistent with previous 
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reports (e.g, 4.2 s, Farsalinos et al., 2013; 4.3 s, Hua et al., 2013). In one previous study 
(Behar, Hua, & Talbot, 2015), ECIG-experienced users exhibited shorter mean puff 
durations (2.7 s) and smaller mean puff volumes (51 ml) relative to those observed in the 
present study’s directed bout (4.5 s and 124.6 ml, respectively). However, these relatively 
shorter and smaller puffs may have been the result of the topography recording device 
used in that study. That is, the CReSS device that was used to record puff topography 
may not have provided sufficient sensitivity to accommodate the low flow-rate puffs 
often observed in ECIG users, as it was designed to accommodate higher flow rates 
consistent with cigarette smoking. Indeed, the relatively lower flow rates that were 
detected in the present study and in a previous report (Behar et al., 2015) highlight the 
need for the use of specialized topography measurement equipment to measure ECIG 
topography accurately.  
  Because previous studies have demonstrated that ECIG-naïve cigarette smokers 
may exhibit different puff topography relative to experienced ECIG users (e.g., 
Farsalinos et al., 2013). Comparisons were made between puff topography recorded in 
the directed bout of the present study among experienced ECIG users to puff topography 
recorded from experienced cigarette smokers who smoked a cigarette ad libitum in a 
previous study (Kleykamp et al., 2008). As Table 4 shows, ECIG users in this study took 
longer, larger, and slower puffs relative to the comparison group of cigarette smokers.  
  Participants’ puff count during ad libitum use was also recorded and compared 
across conditions (puff count was measured observationally in the no mouthpiece 
condition). Results provided no evidence that the topography mouthpiece interfered with 
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puff count. Within the mouthpiece condition, puff topography values recorded from the 
directed bout were compared to those recorded from the ad libitum bout. Differences 
were observed between bouts for puff duration, volume, and IPI. Specifically, 
participants exhibited longer puff durations/IPIs and larger puff volumes in the ad libitum 
bout relative to the directed.  
  The puff topography results from this study have several important implications. 
First, the observed differences in puff topography between experienced ECIG users in 
this study and tobacco cigarette smokers from previous reports (Kleykamp et al., 2008) 
suggest that ECIG users who were previous smokers may learn to adjust their puff 
topography, possibly in order to extract the level of nicotine they were accustomed to 
getting from conventional cigarettes. Importantly, all participants in the present study 
were former cigarette smokers. At least one study has demonstrated that ECIG-naïve 
cigarette smokers when given an ECIG for a period of one week, appear to adjust their 
average puff duration and flow rate in a manner consistent with the results reported here 
(Lee et al., 2015). This apparent learning curve could be problematic for smoking 
cessation purposes, given that ECIGs do not typically provide users with instructions 
regarding proper puffing techniques. Furthermore, future clinical trials testing the 
efficacy of ECIGs for smoking cessation may want to provide participants with puffing 
instructions to maximize their likelihood of obtaining nicotine and/or suppressing 
nicotine withdrawal symptoms, thus potentially limiting attrition, or may need to provide 
participants with a device that will deliver comparable levels of nicotine without 
requiring a change in behavior.  
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  Raising additional implications, participants in the present study exhibited 
significantly larger and longer puffs with greater IPIs when in the ad libitum relative to 
the directed bout. These findings may suggest that controlled ECIG puffing parameters 
used in this study and numerous others (e.g., Vansickel et al., 2010) may inhibit users 
from exhibiting their natural puff topography, even for measures such as puff duration 
that are not intentionally kept consistent. In other words, although controlling certain 
puffing parameters during ECIG use can make comparisons to cigarette smoking easier 
for several outcomes and also increase the internal validity of a study, this controlled puff 
topography may not be indicative of real-world ECIG use. Importantly, previous studies 
have demonstrated that when user puff topography is mimicked precisely and used to 
produce aerosols from other tobacco products (e.g., waterpipe), excellent correlations 
between toxicant yield and user toxicant exposure are observed (Shihadeh & Eissenberg, 
2011). In order to determine accurately the toxicant content of aerosols produced from 
ECIGs and thereby inform ECIG regulation, future studies likely will need to examine 
ECIG use under more naturalistic conditions which may only be possible with an 
ambulatory puff measurement device as has been developed for cigarette smokers (Blank 
et al., 2009). 
  In addition to the topography results mentioned above, this study also 
demonstrated that for virtually all of the measures collected in this study, significant main 
effects of time were observed with very few (2/33 measures) significant interactions 
between time and condition. This lack of significant time by condition interactions 
suggests that there is little evidence from this study that the presence of the mouthpiece-
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based topography measurement device influenced any of the observed acute effects of 
ECIG use including nicotine delivery and subjective and physiological effects. Therefore, 
the section below describing these acute effects will focus on the numerous significant 
main effects of time that were observed.  
Assessment of Acute ECIG Effects 
  Physiological measures. The physiological measures assessed in the present 
study provide evidence regarding acute nicotine exposure and cardiovascular effects 
associated with controlled (10-puff directed bout, 30 sec IPI) and ad libitum ECIG use 
(90 min). Increases in plasma nicotine and HR were seen after each product 
administration.   
  After the 10-puff directed bout, collapsed across condition, a mean increase of 
16.6 ng/ml was observed for plasma nicotine while a mean increase of 7 bpm was 
observed for HR. This observed increase in plasma nicotine after 10 puffs from 
participants’ preferred ECIG battery/solution is consistent with plasma nicotine increases 
observed in cigarette smokers smoking their own brand of cigarettes in previous studies 
(e.g., mean = 16.7 ng/ml; Vansickel et al., 2010). Furthermore, the plasma nicotine 
increases exhibited by these participants were accompanied by increases in HR. Previous 
research has similarly demonstrated that delivery of nicotine from pharmaceutical 
products (Evans et al., 2006) or other tobacco products such as cigarettes (Buchhalter & 
Eissenberg, 2000; Vansickel et al., 2010) is typically associated with increases in HR.  
  During the ad libitum bout, collapsed across condition, a mean peak plasma 
concentration of 35 ng/ml (SD = 23.36) was observed after 90 minutes. Interestingly, the 
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mean peak plasma concentrations detected here are comparable to plasma nicotine levels 
achieved by cigarette smokers during ad libitum cigarette use periods in previous studies 
(e.g., Foulds et al., 1992: mean = 27.0 ng/ml, SD = 9.9, N = 30; Yan & D’Ruiz, 2015: 
mean = 29.2 ng/ml, SD = 10.8; N = 24). Thus, this study demonstrated that in terms of 
nicotine exposure and cardiovascular effects, participants’ preferred ECIG and solution 
resulted in similar physiological effects relative to those observed in cigarette smokers in 
previous studies. 
  Importantly, similar to previous studies (Dawkins & Corcoran, 2013; Farsalinos et 
al., 2014; Vansickel & Eissenberg, 2013), nicotine delivery varied considerably among 
the experienced users in this study. For example, some participants were able to achieve 
much higher plasma nicotine concentrations relative to those seen after smoking a single 
tobacco cigarette (e.g., > 100 ng/ml using 18 mg/ml, PG:VG: 30:70 ECIG liquid with 
3.3V “eGo” battery), while others were only able to obtain minimal doses of nicotine. 
One possible explanation for this variability in nicotine delivery is individual variability 
in puff topography, but given that the devices and liquids used in this study were not 
standardized this relationship was difficult to examine. However, the lack of a significant 
correlation between puff number in the ad libitum bout of each condition and mean peak 
plasma concentration suggest that at least this particular aspect of puff topography does 
not influence nicotine delivery. This variability in nicotine delivery may also be 
explained by the variability in device and solutions used. More specifically, recent 
research examining factors that influence ECIG aerosol nicotine yield (Talih et al., 2015) 
have demonstrated that device characteristics such as battery voltage and heater 
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resistance and solution characteristics such as nicotine concentration can all affect the 
amount of nicotine that emerges from the mouth-end of an ECIG. That is, higher battery 
voltage, lower heater resistance, and higher liquid nicotine concentrations all increase 
nicotine yield. Given that none of these factors were held constant in this study, they all 
likely contributed to the observed variability in nicotine delivery.   
  Subjective effects. Abstinence symptom suppression, direct effects of ECIG use, 
and the direct effects of nicotine were examined using various questionnaires in this 
study. Additionally, in the mouthpiece condition, the extent to which the presence of the 
topography mouthpiece influenced overall acceptability of ECIG use was assessed. 
  Participants’ preferred ECIG and liquid produced reliable abstinence symptom 
suppression for several important VAS items. For example, collapsed across condition, 
mean ratings of “Urge to Vape” decreased by approximately 32 points after the directed 
bout, and an additional 11 points after the ad libitum bout (VAS scale, 0-100). Similar 
pronounced post-ECIG use reductions were observed for the items “Anxious,” “Craving 
an ECIG,” and “Irritable.” The reductions in these withdrawal suppression-indicative 
VAS items are comparable to those observed after smoking a single cigarette in previous 
studies (e.g., Buchhalter, Schrinel, & Eissenberg, 2001; Vansickel et al., 2010). Other 
important subjective effects to examine when assessing a potential MRTP are the direct 
effects of nicotine and the product itself. Numerous items on both the Direct Effects of 
Nicotine Scale and the Direct Effects of ECIG use scale changed significantly following 
ECIG use. That these participants appeared to experience abstinence symptoms as a 
result of abstaining from ECIG use for at least 12 hours and subsequently were able to 
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alleviate these abstinence symptoms after using their device may be an indication of 
nicotine dependence. However, given that all participants in this study were former 
cigarette smokers, it is unclear the extent to which this apparent nicotine dependence was 
already present prior to becoming an ECIG user.  
  Participants also answered several questions in the mouthpiece condition that 
assessed the extent to which they perceived the topography mouthpiece as influencing 
their normal ECIG-use behaviors. No differences were observed between the post-
directed and post- ad libitum VAS scores for any of these items. Taken together, results 
from the subjective questionnaires administered in this study demonstrated that 
participants’ subjective perceptions of their preferred ECIG device following directed and 
ad libitum use were not influenced by the presence of a mouthpiece-based topography 
recording device.  
  Several implications can be drawn from the acute physiological and subjective 
effects associated with ECIG use seen in this study.  First, the levels of nicotine these 
ECIG users were able to obtain from their devices were comparable to those previously 
seen in cigarette smokers using their own brand of cigarettes under similar conditions. 
Specifically, on average, cigarette smokers take 10 puffs from a single cigarette while 
exhibiting approximately 30 second IPIs. Under these same puffing parameters, ECIG 
users in the present study were able to obtain commensurate increases in plasma nicotine, 
suggesting that ECIGs are capable of delivering nicotine rapidly and efficiently to the 
user unlike NRTs (Le Houezec, 2003) or other alternative tobacco products (e.g., oral, 
non-combustibles; Cobb et al., 2010). In addition, when ECIG users were free to puff on 
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their preferred device and ECIG liquid ad libitum, similar peak plasma concentrations 
were detected compared to those seen previously in cigarette smokers left to use their 
own brand of cigarettes in a similar manner. Second, results of the subjective measures 
administered in this study demonstrated that participants’ abstinence symptoms were 
significantly reduced following acute ECIG use, suggesting that these ECIG users may 
have been dependent on nicotine. Additionally, in some instances plasma nicotine 
concentrations observed after ECIG use were much higher than expected from a tobacco 
cigarette. There is not clear rationale for a device that can deliver more nicotine than a 
tobacco cigarette, as higher doses of nicotine could lead to increased risk of nicotine 
dependence (potentially promoting the use of multiple products and/or making cessation 
more difficult) and may also be toxic to a user. 
Limitations 
  Despite the numerous strengths of the present study and useful implications that 
can be drawn from the results, several limitations are also apparent. First, participants 
were permitted to use their preferred ECIG battery and liquid, both of which varied 
considerably. Assessing the relationship between puff topography and nicotine delivery 
was challenging, given that many of the device/solution characteristics that varied 
between participants (e.g., liquid nicotine concentration, liquid PG:VG ratio, battery 
voltage, heater resistance) have all been shown to alter the amount of nicotine ultimately 
found in the aerosol produced by an ECIG (Talih et al., 2015). Future research would 
benefit by attempting to control some of these factors, while manipulating systematically 
another, in order to elucidate that particular factor’s influence on ECIG acute effects. The 
  
58 
 
standardization of the cartomizer used in this study, while necessary to ensure accurate 
topography recording, was another limitation. Participants may have exhibited different 
puff topography or extracted nicotine differently had they used their preferred tank or 
cartomizer. The creation of a mouthpiece-based device that can accommodate more tank-
based and cartomizer-based ECIGs may be necessary for future studies. Additionally, a 
placebo-controlled study would need to be conducted to determine unequivocally that the 
increases in HR and abstinence symptom suppression that were observed were the result 
of nicotine being delivered to the user. Lastly, the laboratory setting is a limitation of this 
study. As stated previously, if ECIG users were able to use their device outside of the lab 
and an ambulatory topography-recording device were used to record their puff 
topography, more naturalistic puff topography data would likely be generated relative to 
the data collected in the present study.   
Conclusions 
  This study used clinical laboratory methods to examine ECIG topography and the 
acute effects of ECIG use including nicotine delivery, physiological effects (HR), and 
subjective effects. Furthermore, the extent to which the presence of a mouthpiece-based 
topography recording device influenced these acute effects was also assessed. Results 
demonstrated that ECIG users in the present study exhibited significantly different puff 
topography from that observed previously in cigarette smokers. Additionally, ECIG-
associated nicotine delivery, HR, most subjective measures, and puff number (during ad 
libitum ECIG-use) were not affected by the presence of the topography mouthpiece. 
Taken together, results from this study support the continued use of mouthpiece-based 
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recording devices for measuring ECIG topography in clinical laboratory research. 
Nonetheless, future research may also benefit from the use of a portable ECIG 
topography-recording device that is capable of recording ECIG users’ topography in a 
more naturalistic setting. Furthermore, the increases in plasma nicotine and reductions in 
abstinence symptoms seen after ECIG use in this study lends further support for the 
argument that ECIGs may be a viable nicotine replacement alternative to tobacco 
cigarettes. 
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Appendix A 
Telephone Screening Form  
 
 
 
 
Introduction: This is a research study about how to best measure how people use e-
cigarettes 
 
Purpose: To compare two methods to measure e-cigarette use behavior 
 
Study Details:  If you are eligible for this study, you will be asked to visit our lab on the 
MCV campus for two sessions.  These sessions will begin at approximately the same 
time each day, will take approximately 3 hours each, and will be separated by at least 48 
hours.  We will ask you to abstain from all tobacco products and e-cigarettes, and all 
nicotine containing products (like the gum or patch) for at least 12 hours before each 
session.  When you arrive to the lab for session, we will ask you to take a simple breath 
test to make sure that you have complied with these restrictions.  Side effects from 
tobacco/nicotine abstinence can include irritability, anxiety and restlessness, excessive 
hunger, difficulty concentrating, and sleep disturbance.  Though uncomfortable, these 
feelings are not medically dangerous. 
 
At the beginning of each session, a nurse will insert an IV catheter into your arm that will 
stay there for the entire session. This catheter will be used to draw blood periodically 
(less than 1 tablespoon per sample, 8 samples). We will also monitor your heart rate and 
blood pressure and ask you to respond to several questionnaires to measure how you feel 
before and after vaping.   There is some risk of bruising at the catheter site, and there is a 
minimal risk of infection associated with any blood draw.     
 
For the session, we will ask you to provide your own e-cig with a fully charged battery. 
We will provide to you a new cartridge or cartomizer of the brand, flavor, and nicotine 
dose that you choose. During the session we will ask you to vape using your e-cig at two 
separate times.  
 
When you smoke your e-cigarette, you may notice that it is connected to a computer and 
that there are pieces of equipment attached to the e-cigarette.  The computer and this 
equipment are measuring how you vape (the size and number of the puffs that you take).  
Also, we will record on video your smoking behavior in both sessions.  These video 
recordings will also be used to measure how you vape (for example, the number of puffs 
that you take).   
 
Confidentiality:  We will not tell anyone the answers that you give us; however, 
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information from the study and the consent form signed by you may be looked at or 
copied for research or legal purposes by the sponsor of the research, or by Virginia 
Commonwealth University. 
 
Payment:  You will receive $100 after completing the first session and $150 after 
completing the second session.  Thus, the total amount earned for finishing the entire 
study is $250. 
 
“Does this sound like something you want to participate in?” 
 
Document caller’s response by circling either:      
Yes      or      No 
If yes, continue with the following questions. 
 
 
Telephone Screening Questionnaire 
 
Interviewer:  “I would like to ask you some questions about yourself and your health 
status as well as your use of e-cigarettes, tobacco, alcohol, and other drugs.  Completion of 
these questions will take approximately 10 minutes of your time.  The purpose of these 
questions is to determine whether or not you are eligible to participate in the study I just 
described, in addition to other studies currently ongoing in our laboratory  All of your 
responses are confidential.  You are not required to answer any question and you may stop 
this interview at any time. May I begin the questions?” 
 
Document caller’s response by circling either:     Yes      
or      No 
 
If Yes: begin form.  If No: thank caller for calling. 
 
 
How did you hear about us/our studies?   
 ________________________ 
 
Personal Information: 
1.  “What is your first name?”     
 ________________________ 
 
2.  “What is a phone number at which you can be contacted?” 
 ________________________ 
 
4.  “If we call and you are not available, may we leave a message?”   Circle Yes      
or      No 
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5.  “What is your date of birth?”     
 ________________________  
 
6.  “What is your height?”       __________ (feet and 
inches)  
 
7.  “What is your weight?”       __________ (pounds) 
 
8. “Which identifier best describes you?”    Male    or   Female    
 
9.  “Did you graduate high school?”        Circle Yes      
or      No 
 
If Yes: Skip the next question. 
 
10.  “Did you obtain your GED?”:      Circle Yes      
or      No 
General health status: 
 
11.  “Do you have any chronic health concerns or problems?”  Circle Yes      
or      No 
 
  If Yes: “Please describe the concern or problem”: 
 
12.  “Are you under a doctor’s care for a medical condition?”   Circle Yes      
or      No 
 
  If Yes: “Please describe the condition”: 
 
13.  “Are you taking any prescription or over-the-counter medications?” Circle Yes      
or      No 
 
  If Yes: “Please identify the medication”: 
 
14.  Do you have any psychiatric conditions like depression or anxiety?    
           
 Circle Yes      or      No 
  If Yes: “Please describe the condition”: 
 
15.  “Have you ever been diagnosed with high or low blood pressure?”  Circle Yes      
or      No 
 
  If Yes: “Please indicate whether it is high or low”: 
 
Cigarette use: 
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16. Have you smoked tobacco cigarettes in the past year?   Circle Yes   or    
No 
  If Yes: “When was the most recent occasion you smoked tobacco 
cigarettes? 
 
Circle: Within the past 30 days    or    2 to 3 months ago    or   4 to 6 months ago   or  
More than 6 months ago 
 
  If No: Go to Question 19 
 
17.  “How many cigarettes/day do you smoke?” Write in exact number and also circle 
appropriate category:   ________ (num of cigs) 
 
   10 or less  11-20  21-30  31 or more 
 
18.  “For how long have you smoked this number?”     
 
 
19.  “Have you ever used an electronic cigarette?”    Circle Yes      
or      No 
 
  If Yes:ask the following questions 
 
  “What is your preferred e-cig brand?”     
 
  “Do you ever use other brands of e-cig?”    
 
  “What is your preferred cartridge or e-liquid strength?”  
 
  “Do you ever use other strengths?”     
 
“On average, how many cartridges or ml of nicotine solution do you vape per 
day? (Please indicate liquid or cartridge)”      
 
  “For how long have you vaped this amount?”  
 
  “Where do you purchase your e-cig cartridges and/or nicotine solution?”  
 
 
Interviewer: “I am now going to ask questions about alcohol and drug use.  Please 
remember that you are not required to answer any question and you may stop this 
interview at any time.” 
 
Alcohol use: 
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20.  “Have you ever been treated for alcohol abuse/dependence?”  Circle Yes      
or      No 
 
  If Yes: “When was your treatment completed?”:  mnth/year) 
 
21.  “Do you use (drink) alcoholic beverages?”    Circle Yes      
or      No 
 
  If No: Skip the remainder of this section. 
 
22.  “How many alcoholic drinks (by alcohol I mean beer, wine, or liquor) 
 do you have on a typical day? (num of drinks) 
 
23.  “How many days out of the last 30 have you used alcohol? (num of days) 
 
Marijuana use: 
24.  Have you ever, in your lifetime, smoked marijuana or hashish? Circle Yes      or      
No 
 
  If No: Skip the next question. 
 
25.  “How many days out of the last 30 have you smoked marijuana?” (number of days) 
 
 
Other drug use: 
26.  “Have you used any other illegal drugs within the past month?” Circle Yes      
or      No 
 
  If Yes: “Please identify which drug or drugs.” 
 
For women only: 
27.  “Are you currently pregnant?”      Circle Yes      
or      No 
 
28.  “Are you currently breast-feeding a child?”    Circle Yes      
or      No 
 
29.  “What was the first day of your last period?”     
 
Interviewer:  “Thank you for responding to these questions.  I need to pass on your 
responses to the principal investigator who will then determine whether or not you are 
eligible to participate in a study; someone will contact you within approximately one 
week if you are eligible.  If you are not eligible for any of our current studies, then you 
will not be contacted.” 
 [If respondent does not have a phone, they can call us back in a few days] 
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Appendix B 
Informed Consent form  
 
Title. Measurement of electronic cigarette (ECIG) use topography 
 
VCU IRB Number: HM 15411 
 
Investigator. Dr. Thomas Eissenberg 
 
Sponsor.  National Institutes of Health 
 
This consent form may contain words that you do not understand. Please ask the study 
staff to explain any words that you do not clearly understand. You may take home an 
unsigned copy of this consent form to think about or discuss with family or friends 
before making your decision. 
 
Purpose of the study.  The purpose of this research study is to learn about how you 
use electronic cigarettes and what effects they produce. 
 
Description of the study and procedures. If you agree to join the study, you will be 
asked questions about your general health, smoking history, and marijuana and 
alcohol use.  If you are a woman you will need to provide a urine sample that will be 
tested immediately for pregnancy. If you are pregnant you cannot participate in this 
study. Your responses will be confidential. 
 
If the urine tests and your answers to our questions indicate that you fulfill the entry 
criteria, we will ask you to participate in two, approximately 3-hour sessions here at the 
Clinical Behavioral Pharmacology Laboratory located on VCU’s medical campus. The 
two sessions will begin at approximately the same time each day, and will be separated 
by at least 48 hours.  Before each session, we will ask you to abstain from all electronic 
cigarette and other tobacco products for at least 12 hours.  We will also ask you to 
abstain from all food and caffeinated beverages for 1 hour before each session.  In 
addition, the use of any nicotine-containing products (like the gum or patch) is 
prohibited. We will ask you to take a simple breath test to make sure that you have 
complied with these restrictions. Our tests are not perfect, but they are the only 
measures that we can accept to make certain that you have complied with the no 
tobacco/no nicotine restrictions. 
 
At the beginning of the session, a nurse will insert an IV catheter into your arm that will 
stay there for the entire session. This catheter will be used to draw blood periodically 
(less than 1 tablespoon per sample, 8 samples). We use this method because participants 
tell us that it is more comfortable than repeated “sticks” with a needle. During this 
session we will take much less blood than the amount you would give in a single 
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donation at a blood drive. We will also monitor your heart rate and blood pressure and 
ask you to respond to several questionnaires to measure how you feel before and after 
you use an electronic cigarette. 
 
For the session, we will ask you to provide your own electronic cigarette with a fully 
charged battery. If you think you need additional batteries, please bring them with you.  
We will provide to you a new cartridge or cartomizer of the brand, flavor, and nicotine 
dose that you choose. During the session we will ask you to use your electronic 
cigarette at two separate times. The first time, we will ask you to take only 10 puffs, 
and we will tell you when to take each of these puffs. The second time we will ask you 
to use the electronic cigarette however you’d like. If you need another cartridge or 
cartomizer during this time, please let us know and we will provide it to you.  At each 
of these two times we need you to remain seated in a comfortable chair while you are 
using the electronic cigarette. 
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Appendix C 
Hughes-Hatsukami Withdrawal VAS Scale (Hughes & Hatsukami, 1986).  
          
 
 
   
Not at  
 
All   Extremely   
         
1.    Urges to use an e-cigarette           
           
         
2.    Irritability/frustration/anger           
           
         
3.   Anxious            
           
         
4  Difficulty Concentrating           
           
         
5.  Restlessness            
           
         
6.    Hunger            
           
         
7.    Impatient            
           
         
8.    CRAVING an e-cigarette           
           
         
9.   Drowsiness            
           
         
10.  Depression/ feeling blue           
           
         
11.  Desire for Sweets           
           
 
These phrases may or may not describe how you feel right now. 
Please respond to each word of phrase with how you feel RIGHT 
NOW 
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